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Saoirse E. O’Sullivan
Division of Medical Sciences and Graduate Entry Medicine, School of Medicine, University of Nottingham, Royal Derby 
Hospital, Derby, United Kingdom
Background: Osteocalcin (OC) is an intriguing hormone, concomitantly being the 
most abundant non-collagenous peptide found in the mineralized matrix of bone, and 
expanding the endocrine function of the skeleton with far-reaching extra-osseous effects. 
A new line of enquiry between OC and vascular calcification has emerged in response 
to observations that the mechanism of vascular calcification resembles that of bone 
mineralisation. To date, studies have reported mixed results. This systematic review and 
meta-analysis aimed to identify any association between OC and vascular calcification 
and atherosclerosis.
methods and results: Databases were searched for original, peer reviewed human 
studies. A total of 1,453 articles were retrieved, of which 46 met the eligibility criteria. 
Overall 26 positive, 17 negative, and 29 neutral relationships were reported for assess-
ments between OC (either concentration in blood, presence of OC-positive cells, or 
histological staining for OC) and extent of calcification or atherosclerosis. Studies that 
measured OC-positive cells or histological staining for OC reported positive relationships 
(11 studies). A higher percentage of Asian studies found a negative relationship (36%) in 
contrast to European studies (6%). Studies examining carboxylated and undercarboxyl-
ated forms of OC in the blood failed to report consistent results. The meta-analysis found 
no significant difference between OC concentration in the blood between patients with 
“atherosclerosis” and control (p = 0.13, n = 1,197).
conclusion: No definitive association was determined between OC and vascular cal-
cification or atherosclerosis; however, the presence of OC-positive cells and histological 
staining had a consistent positive correlation with calcification or atherosclerosis. The 
review highlighted several themes, which may influence OC within differing populations 
leading to inconclusive results. Large, longitudinal studies are required to further current 
understanding of the clinical relevance of OC in vascular calcification and atherosclerosis.
Keywords: osteocalcin, calcification, atherosclerosis, bone hormone, vascular disease, bone glutamic acid 
protein
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iNtRODUctiON
Vascular calcification is a known major risk factor for mortality 
and morbidity and is an independent risk factor for cardiovascular 
disease (1–3). Vascular calcification, long believed to be a passive 
part of aging and “wear and tear,” is now considered an active, 
cell-mediated complex process that is regulated but not yet fully 
understood. Osteocalcin (OC) [also known as bone glutamic acid 
protein (BGLAP)] is an intriguing hormone produced by osteo-
blasts in bone that has been recently linked with an increasing 
number of extra-osseous biological roles and effects (4–8). One 
candidate thread of enquiry is its interaction with the vascular 
system, and its putative role in the process of vascular calcifica-
tion or atherosclerosis. OC is not only produced by bone but is 
expressed by vascular smooth muscle cells (VSMCs) displaying 
an osteoblast-like phenotype (9).
Osteocalcin is the most abundant, non-collagenous compo-
nent in the mineralized matrix of bone (10). The presence of 
three glutamic acid (Gla) residues allows for posttranslational 
γ-carboxylation at positions 17, 21, and 24. Between 60 and 90% 
of carboxylated OC (cOC) is deposited in the bone matrix; how-
ever, it can also be released into the circulation (11). OC can be 
undercarboxylated (ucOC) to differing degrees (from 0 to 2 car-
boxyl groups) due to decarboxylation, low activity of the vitamin 
K-dependent carboxylase enzyme, or vitamin K deficiency. ucOC 
has less affinity to hydroxyapatite and is more readily released 
into the circulation than cOC (12, 13).
ucOC has recently been appointed a predictor and potential 
therapeutic target of a number of diseases including diabetes and 
is believed to be the active form of OC (14). Studies have shown 
ucOC to be a regulator of pancreatic β cell and adipocyte gene 
expression, glucose metabolism and to increase insulin sensitivity 
in humans (14). Structural inconsistencies between ucOC and 
cOC have been explored, but discrepancies in reports are numer-
ous and it is unknown the extent to which structural differences 
may play in their biological functions (15). It is hypothesized that 
ucOC may be the active form of OC involved in vascular calcifica-
tion, but this has yet to be investigated.
Having established roles of other Gla containing proteins, 
such as Matrix Gla protein, in vascular calcification, many 
researchers have begun to explore the role of OC. Idelevich et al. 
investigated the effects of OC overexpressing mice cell lines 
(chondrocytes and VSMCs) (16). They showed that OC stimulates 
VSMC mineralization and differentiation, in particular through 
HIF-1α activation, surmising that OC fuels glucose utilization in 
VSMCs and promotes osteochondrogenic differentiation result-
ing in calcification. However, further studies are greatly lacking.
The aim of this systematic review and meta-analysis was to 
investigate and critically appraise the available literature linking 
OC to calcification and atherosclerosis in humans.
metHODS
Search Strategy
The systematic review was carried out in accordance with the 
Meta-analysis Of Observational Studies in Epidemiology group 
proposal for reporting (17). A systematic and comprehensive 
search of PubMed and EMBASE (including Medline) was con-
ducted to extract all articles examining an association between 
OC and vascular calcification or atherosclerosis. Identical search 
terms were used for both databases and included: “Osteocalcin 
AND Vascular Calcification,” “Osteocalcin AND Atherosclerosis,” 
“Osteocalcin AND Arterial Stiffness,” “Bone Gla Protein AND 
Vascular Calcification,” “Bone Gla Protein AND Atherosclerosis,” 
“Bone Gla Protein AND Arterial Stiffness,” “BGLAP AND 
Vascular Calcification,” “BGLAP AND Atherosclerosis,” “BGLAP 
AND Arterial Stiffness,” “Bone gamma-carboxyglutamic acid 
protein AND Vascular Calcification,” “Bone gamma-carbox-
yglutamic acid protein AND Atherosclerosis,” “Bone gamma-
carboxyglutamic acid protein AND Arterial Stiffness,” “BGP 
AND Vascular Calcification,” “BGP AND Atherosclerosis,” “BGP 
AND Arterial Stiffness.” The searches were limited to include 
only human studies; with no restrictions on publication year, 
language, population or article type. Articles were subsequently 
excluded if the full text could not be found in English (n = 4). 
The searches were carried out by the 25/05/2017 with no year 
restrictions.
eligibility criteria
The titles and abstracts for returned items were examined, and 
inappropriate articles were rejected. The criteria for inclusion 
was such that the article was an original, peer reviewed paper 
involving either longitudinal or cross-sectional human studies 
that investigated the relationship between OC and calcification 
or atherosclerosis. A further requirement of each study was that 
a form of OC must have been measured within their sample 
population. An endpoint relating specifically to the degree or 
severity of calcification or atherosclerosis was required to have 
been measured and reported. Studies that used assumptions 
of an increased risk of cardiovascular disease (CVD), e.g., by 
age and weight within their sample populations were excluded. 
All searches were conducted independently by two reviewers 
and compared. Where differing opinions on study eligibility 
existed (n =  6), they were discussed with the study principle 
investigator.
Data extraction and analysis
The included articles were analyzed, and data were collated using 
an extraction form. The extracted data included the following: 
the population characteristics (age, sample size, ethnicity, and 
health status); type and method of OC measured; endpoint 
measurements; results of outcome and exposure measures; 
and the overall conclusions of the article and any key limita-
tions or bias. A risk of bias assessment was performed accord-
ing to the Cochrane Collaboration’s tool for assessing risk 
of bias (18).
Statistical analysis
A meta-analysis was performed on those studies that provided 
OC concentration in blood samples from an “increased vascular 
calcification/atherosclerosis group” and from a “control/healthy 
group.” Data were analyzed as forest plots using the Cochrane 
Review Manager software (Version 5.3. Copenhagen: The Nordic 
FigURe 1 | Flow chart for study retrieval and selection. Abbreviation: OC, osteocalcin.
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Cochrane Centre, The Cochrane Collaboration, 2014) and as fun-
nel plots using Stata (StataCorp., 2009. Stat Statistical Software: 
Release 11. College Station, TX, USA). Funnel plot asymmetry 
(publication bias) was tested by Egger’s test (19). Since heteroge-
neity was expected between study protocols (different population 
characteristics, different methods of defining calcification or athe-
rosclerosis, different specificity of assessment methods of OC) 
random-effect models were used. The results of continuous data 
of OC concentration are expressed as mean and SD. Where stud-
ies did not provide mean and SD, authors were contacted for data. 
In cases where no response from authors was obtained (n = 8), 
they could not be included in the statistical analysis (20–27). One 
author declined to supply requested information (28). Studies 
were weighted by sample size, and statistical significance was set 
at p < 0.05. The results are expressed as mean difference as all 
studies reported OC concentrations in the same units. It was not 
possible to perform further analyses due to large heterogeneity 
between studies.
ReSULtS
The initial search yielded 1,453 records from which 374 abstracts 
were reviewed and 46 articles met the inclusion criteria (Figure 1). 
A description of each study is provided in Table 1. Of the 46 stud-
ies included in this review, 26 (56%) were designed specifically to 
examine the relationship between OC and markers of calcification 
or atherosclerosis (20, 22, 24–27, 29–47). The other 20 studies 
evaluated OC among a number of measurements, as a covari-
ate, or in secondary analyses (21, 23, 28, 48–61). Forty-four out 
of the 46 studies were cross-sectional in design. Twenty-four 
studies did not make adjustments for any potential confounding 
variables, and 22 conducted multivariate analyses (Table 1). Ten 
studies had a sample size greater than 300 (20, 24, 25, 27, 30, 33, 
35, 43, 45, 62).
Thirty-three studies (72%) measured OC by enzyme-linked 
immunosorbent assay, electrogenerated chemiluminescence, 
or radioimmunoassay, while the remaining studies used flow 
taBLe 1 | Summary of included studies.
Reference n Sex Location inclusion criteria Oc 
measurement
Oc type calcification or 
atherosclerosis 
measurement
Study outcomes adjustments
Levy et al. (46) 38 M, F USA Autopsy samples RIA Total CS OC was present in all calcified aortic 
tissue and heart valves and was either not 
detectable or present at very low levels in 
non-mineralized lesions and normal tissue
None
Jie et al. (36) 256 F Netherlands >55 years old RIA Total, free, 
and bound
CS None Age
Watson et al. (49) 173 M, F USA High and moderate 
risk for CHD
RIA Total CS None None
Bini et al. (57) 22 Not 
specified
USA Human carotid 
endarterectomy 
specimens
Immunostaining Total CS OC positively associated with calcification, 
progressing from type V to type VI lesions
None
Montalcini et al. (50) 157 F Italy Postmenopausal 
women aged 
45–75 years
RIA Total C-IMT Positive relationship between OC and 
carotid atherosclerosis prevalence in those 
with low BMD
Age, systemic hypertension, 
hyperlipidemia, DM, obesity, 
smoking
Iba et al. (56) 135 F Japan Postmenopausal 
osteoporotic women
ELISA Total ACS None None
Rajamannan et al. (59) 58 M, F USA T2DM, >18 years old, 
cardiac valve surgery
Immunostaining Total CS OC expression was upregulated in the 
calcified rheumatic valves and was present 
at low levels in the degenerative mitral 
valves
None
Göossl et al. (37) 72 M, F USA Coronary 
atherosclerosis 
patients
Flow cytometry OCN+ EPCs CA and endothelial 
function
Positive relationship between OC+ cells 
and stage of coronary atherosclerosis
None
Kanazawa et al. (35) 328 M, F Japan T2DM RIA Total PWV and C-IMT Negative correlation between OC and  
PWV and C-IMT in men only
None
Pal et al. (40) 23 M, F Australia Peripheral artery 
disease
Flow cytometry OC + MNCs ACS Positive relationship between OC+ cells 
and aortic calcification
None
Foresta et al. (38) 35 M Italy Erectile dysfunction 
patients
Flow cytometry OC + EPCs C-IMT Positive relationship between OC+ cells 
and IMT
None
Zhang et al. (25) 461 M, F China Chest pain, heaviness, 
periodic discomfort, 
and palpitations
ELISA Total CA OC was significantly higher in those with 0 
diseased vessel than in those with 1,2, or 
≥3 diseased vessels
None
Parker et al. (27) 363 F USA ≥65 years old ELISA Total ACS None Age, CVD risk factors, BMD, 
mineral metabolism, estrogen 
use, kidney function, vitamin D, 
PTH, and BSAP
Okura et al. (31) 92 M, F Japan Essential hypertension ELISA ucOC C-IMT Positive relationship between ucOC levels 
and calcification
None
Awan et al. (55) 19 M, F Canada Familial 
hypercholesterolemia
ELISA Total CACS Negative correlations between ACS  
and OC
None
(Continued)
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Reference n Sex Location inclusion criteria Oc 
measurement
Oc type calcification or 
atherosclerosis 
measurement
Study outcomes adjustments
Bao et al. (26) 181 M China MS, CA ELISA Total CA Negative relationship between OC and 
number of stenotic vessels in subgroup 
analysis with NGTnormal glucose tolerance 
(n = 60)
None
Pirro et al. (61) 120 F Italy Newly diagnosed, 
never-treated 
postmenopausal 
osteoporosis
FACS OCN+ OPCs PWV Moderate positive correlation between 
AoPWV and OC+ cells
Age, smoking status, waist 
circumference, SBP (or 
alternatively MABP), heart 
rate, glucose, cholesterol, TG, 
PTH, osteoporotic status, and 
the log-transformed count of 
CD34+/AP+ cells
Kanazawa et al. (47) 50 M, F Japan T2DM RIA Total C-IMT Positive correlation of baseline plaque 
score with changes in OC,a and negative 
correlation of changes in OC with changes 
in plaque scoreb
a,b
Reyes-Garcia et al. 
(34)
78 M, F Spain T2DM RIA Total C-IMT Positive association between OC and IMT, 
carotid plaques, and aortic calcifications, in 
women only
None
Kim et al. (30) 769 F Korea Women ELISA Total ACS Negative relationship between OC and 
ACS
Age
Ogawa-FuruyaOgawa 
et al. (29)
218 M, F Japan T2DM RIA Total, ucOC ACS Negative association between both serum 
OC and ucOC concentrations and an ACS 
of 3 and greater, in men only
Age, BMI, serum creatinine and 
LDL-c, radial BMD, smoking, 
duration of DM, HbA1c, and 
HOMA-IR
Janda et al. (48) 67 M, F Poland >18 years old, PD 
≥2 months, negative 
history of neoplastic 
diseases
ELISA Total C-IMT OC positively associated with C-IMT Age and major CVD risk factors
Sheng et al. (33) 817 M, F China >50 years old, T2DM RIA Total C-IMT and plaques Negative association between OC, carotid 
plaques,c and C-IMTd
c,d
Janda et al. (23) 59 M, F Poland ESRD ELISA Total CS None Low HDL-c (<1.0 mmol/L in 
men, <1.3 mmol/L in women), 
high TG (>1.7 mmol/L), and 
high BMI (≥25 kg/m2), as well 
as hypertension, CRP, gender, 
dialysis status of patients, and 
Ca × Pi
Foresta et al. (39) 3 M Italy Carotid 
endarterectomy
Immunostaining Total CS Positive relationship observed between 
OC and extent of calcification in lesions/
necrotic core (no OC detected in 
corresponding healthy portions of carotid 
wall specimens)
None
taBLe 1 | Continued
(Continued)
5
M
illar et al.
O
C
 and Vascular C
alcification
Frontiers in Endocrinology | w
w
w
.frontiersin.org
July 2017 | Volum
e 8 | A
rticle 183
Reference n Sex Location inclusion criteria Oc 
measurement
Oc type calcification or 
atherosclerosis 
measurement
Study outcomes adjustments
Yang et al. (20) 1,319 F China Postmenopausal 
women
ELISA Total C-IMT Negative correlation between OC and 
C-IMT
Age, years since menopause, 
BMI, waist circumference, 
SBP, DBP, homeostasis 
model assessment, insulin 
resistance, TG, HDL-c, CRP, 
smoking, antidiabetic therapy, 
antihypertensive therapy, lipid 
lowering therapy, and family 
history of CVD
O’Neill and Adams (58) 19 F USA Mastectomy, partial 
mastectomy, or 
lumpectomy patients 
and a diagnosis of 
ESRD or CKD
Immunostaining Total CS OC positively related with more heavily 
calcified arteries and appeared to coincide 
with calcium deposits
None
Ishimura et al. (28) 167 M Japan Stable HD for 
>3 months
RIA Total CS None None
Dweck et al. (54) 30 M, F UK Valve replacement 
surgery or 
asymptomatic disease 
under surveillance
Immunostaining Total 18F-NaF Positive relationship between aortic valve 
18F-NaF uptake and OC
None
Krzanowski et al. (51) 57 M, F Poland >18 years old, stable 
dialysis ≥2 months, 
negative history of 
malignant disease, 
and lack of active viral 
infection
ELISA Total PWV Negative relationship between OC and 
PWV
Age, hypertension, MABP, 
AoPWV evaluation, 
hypertension, ln (dialysis 
therapy duration), dialysis fluid 
exchange method, and Ca Pi 
index
Ma et al. (24) 1,077 M China Males with and 
without NGT
ELISA Total C-IMT and plaques Negative relationship between OC and 
carotid plaque in subgroup analysis with 
men with NGT (n = 638). No associations 
with C-IMT
Age, BMI, WHR, FBG, PPG, 
SBP, DBP, TG, HDL-c, LDL-c, 
smoking, logHOMA-IR, and 
logHOMA-%B
Prats-Puig et al. (32) 203 M, F Spain 5–10 years old, MS 
families, and no 
pubertal development
ELISA Total, ucOC C-IMT ucOC positively associated with C-IMT 
in MS+ family offspring. Total OC not 
associated
Age, gender, BMI, fat mass, 
HOMA-IR, serum lipids, and 
CRP
Choi et al. (41) 162 M, F Korea Healthy adults ECL and ELISA OC, ucOC CACS Positive relationship between OC and 
CACS in men only. No significant findings 
for ucOC
Age, BMI, smoking, 
hypertension, diabetes, SBP, 
HOMA2-IR (log-transformed), 
TG (log-transformed), HDL-c, 
and lumbar BMD
taBLe 1 | Continued
(Continued)
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Reference n Sex Location inclusion criteria Oc 
measurement
Oc type calcification or 
atherosclerosis 
measurement
Study outcomes adjustments
Zhang et al. (42) 224 M, F China CA Flow cytometry OC + EPCs CACS No correlation between OC+ cells with 
calcification in stable angina pectoris 
patients. In unstable angina pectoris and 
acute myocardial infarction patients, the 
number of spotty calcium deposits was 
significantly positively correlated with the 
absolute numbers of OC+ cells
None
Maser et al. (60) 50 M USA >18 years old, T2DM ELISA Total, ucOC CACS None Age, duration of diabetes, 
HOMA-IR, BMI, gender, SBP, 
HbA1c, leptin, and adiponectin
Collin et al. (52) 23 M, F USA 18–85 years old, early 
atherosclerosis
Flow cytometry OC + MNCs CA, endothelium 
dependent 
coronary 
vasoreactivity
Positive relationship between OC+ 
cells and extent of necrotic core and 
calcification
None
Luo et al. (45) 476 M, F China BMI ≥18.5 and 
<25.0 kg/m2, NGT, 
normotensive, and 
normal lipid status
ELISA Total C-IMT None Age, BMI, W, SBP, DBP, FPG, 
serum fasting insulin, CRP, 
smoking status, and CVD 
family history
Zhang et al. (22) 290 M, F China Non-dialysis CKD 
patients
ELISA ucOC C-IMT Negative relationship between ucOC and 
carotid plaquese and IMTf
e,f
Janda et al. (21) 59 M, F Poland HD and PD patients ELISA Total C-IMT No significant correlations FBG, PTX3, FRS, and dialysis 
status
Yang et al. (53) 421 M, F China CA and 
echocardiography
ELISA Total Echocardiography Positive relationship between OC and 
aortic valve stenosis
None
Ramirez-Sandoval 
et al. (63)
76 M, F Mexico PD patients 
≥6 months; stable 
clinical course 
≥3 months
Luminometry Total CS None None
Golovkin et al. (64) 112 M Russia CAD patients ELISA Total CS Levels of OC higher in patients with mild 
CS than those with severe calcification 
when assessed by Agatston score, but not 
Syntax score
None
Barbarash et al. (65) 112 M Russia Age ≤75 years; 
diagnosis of stable 
angina according 
to the Canadian 
Cardiovascular 
Society guidelines
ELISA Total CS None None
taBLe 1 | Continued
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Reference n Sex Location inclusion criteria Oc 
measurement
Oc type calcification or 
atherosclerosis 
measurement
Study outcomes adjustments
Yun et al. (43) 3,604 M, F Korea Healthy adults ECL Total PWV OC level independently related to arterial 
stiffness; inverse J shape relationship. 
At low OC levels, the relationship was 
negatively linear. However, after controls for 
age and metabolic factors, the relationship 
with arterial stiffness at high levels of OC 
was not significant
Age, BMI, SBP, glucose, TV, 
eGFR, smoking, drinking, 
exercise, menopause, history of 
hypertension and diabetes, and 
total hip BMD
Kim et al. (44) 122 M Korea CABG ELISA cOC, ucOC CACS No significant differences in ucOCN or 
cOCN levels between groups divided 
according to CAC score
Age, BMI, T2DM status, 
hypertension, SBP, DBP, 
HbA1c, TC, creatinine, and 
statin therapy
Yang et al. (62) 593 M, F USA Patients undergoing 
CA because of known 
or suspected CAD
Flow cytometry Total CAS OC+ early EPCs associated with an 
increase in levelsg and riskh of higher 
degree of severity of CAS
g,h
M, male; F, female; T2DM, type 2 diabetes mellitus; RIA, radioimmunoassay; ucOC, undercarboxylated osteocalcin; ACS, aortic calcification score; ELISA, enzyme-linked immunosorbent assay; C-IMT, carotid intima-media thickness; 
MS, metabolic syndrome; PD, peritoneal dialysis; CA, coronary angiography; PWV, pulse wave velocity; CS, calcification score; OC, osteocalcin; EPC, endothelial progenitor cells; FACS, fluorescence activated cell sorting; MNCs, 
mononuclear cells; cOC, carboxylated osteocalcin; CACS, coronary artery calcification score; ECL, electrogenerated chemiluminescence; CABG, coronary artery bypass grafting; BMI, body mass index; CKD, chronic kidney disease; 
HD, hemodialysis; ESRD, end-stage renal disease; OPCs, osteoprogenitor cells; LDL-c, low density lipoprotein cholesterol; BMD, bone mineral density; HOMA-IR, homeostasis model assessment index for insulin resistance; CVD, 
cardiovascular disease; PTH, parathyroid hormone; BSAP, bone-specific alkaline phosphatase; CRP, C-reactive protein; HDL, high-density lipoprotein; CHD, coronary heart disease; NGT, normal glucose tolerance; WHR, waist-to-hip 
ratio; FBG, fasting blood glucose; PPG, oral glucose challenge; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglycerides; HOMA-%B, beta cell function; eGFR, estimated glomerular filtration rate; W, weight; MABP, 
mean arterial blood pressure; TC, total cholesterol; PTX3, pentraxin 3; FRS, Framingham Risk Score; CAD, coronary artery disease; CAS, coronary artery stenosis.
aDuration of diabetes and Brinkman index.
bAge, duration of diabetes, gender, BMI, Brinkman index, SBP, serum creatinine, LDL-c, HDL-c, TG, and HbA1c.
cAge, gender, smoking, alcohol intake, duration of diabetes, BMI, waist circumference, SBP, DBP, HOMA-IR, CRP, FBG, serum creatinine, serum urea, serum cholesterol, TG, HDL-c, and LDL-c.
dAge, gender HbA1c, HOMA-IR, and serum CRP.
eAge, sex, BMI, smoking history, MABP, eGFR, therapeutic medication use, FBG, TC, TG, LDL-c, HDL-c, and hs-CRP levels.
fAge.
gNone.
hAge, sex, hypertension, diabetes, hypercholesterolemia, smoking, obesity, and family history of premature CAD.
taBLe 1 | Continued
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cytometry or fluorescence activated cell sorting methods, or 
examined OC by histological immunostaining (Table 1). OC was 
measured using luminometry in one study (63). ucOC was meas-
ured in five studies (22, 31, 32, 41, 44), cOC in one study (44), and 
total OC was measured in the remaining studies (Table 1). OC 
positive mononuclear cells, endothelial progenitor cells (EPCs), 
or osteoprogenitor cells (OPCs) were examined by seven studies 
(37, 38, 40, 42, 52, 61, 62).
Methods of calcification or atherosclerosis measurements 
used in OC analyses varied and ranged from calcification scor-
ing methods (n =  22), intima-media thickness measurements 
(n =  14), pulse wave velocity (PWV) measurements (n =  4), 
plaque presence (n = 2), and coronary angiography or echocar-
diography (n = 6; Table 1). One study used 18F-Sodium Fluoride 
uptake as a marker of calcification (54).
Risk of Bias assessment
Results of the risk of bias assessment for all 46 studies are 
presented in Figure  2. Due to the majority of studies being 
cross-sectional in design and limitations on sample sizes, only 
one study randomly selected participants. Since all the included 
studies were observational cohort studies, no risk of bias 
assessment for “Allocation concealment” could be performed. 
Forty-six percent of studies included a component of blinding. 
None of the studies were reported with high risk of attrition 
bias or other bias. Four studies were reported with high risk of 
reporting bias. Overall, most information was from studies at 
low risk of bias.
Relationship between Oc and markers  
of atherosclerosis or calcification
Results of the meta-analysis examining OC concentrations 
between groups with normal vascular parameters and those 
presenting with markers of calcification/atherosclerosis are 
detailed in Figure 3. There was no significant overall difference 
between OC concentration (total, ucOC, or cOC) in patients 
with “atherosclerosis” and control, though a trend toward lower 
OC concentrations was seen in the control group [overall mean 
difference 0.93 ng/mL (95% CI −0.28, 2.15), p = 0.13]. There was 
significant statistical heterogeneity, I2 88%, p < 0.00001. Egger’s 
test showed no publication bias present (p = 0.279, Figure 4).
Due to multiple end points and assessments within studies, 
results are reported in terms of total outcomes to avoid bias 
reporting of overall positive, negative or neutral findings per 
study in the semiquantitative analysis. Among the studies, the 
relationship between OC and markers of atherosclerosis or cal-
cification was reported as positive for 26 outcomes and negative 
for 17 outcomes, while no relationship was established for 29 
outcomes.
No significant relationship was established for cOC, which 
was measured by only one study (44). In seven studies that meas-
ured ucOC and markers of atherosclerosis or calcification, two 
positive outcomes were reported (31, 32), three negative outcomes 
(22, 29), and four non-significant outcomes (41, 44, 60). Fifty-
four percent of studies did not adjust for any confounding 
variables (Table 1). Of these, 17 positive outcomes between OC 
and markers of atherosclerosis or calcification were reported, 5 
negative outcomes, and 12 non-significant outcomes. Within 
the other 22 studies adjusting for age and/or other confounding 
variables including CVD risk factors, 8 positive outcomes were 
reported between OC and markers of atherosclerosis or calcifica-
tion, 11 negative outcomes were reported, and 17 outcomes were 
non-significant.
All 13 studies measuring OC positive mononuclear cells, 
EPCs, or OPCs, or histological staining for OC, reported a posi-
tive relationship between OC and markers of atherosclerosis.
A number of different outcomes were reported within the 
same studies, depending on gender, type of OC measured, or type 
of calcification or atherosclerosis measurement. Ogawa-Furuya 
et al. (29) and Kanazawa et al. (35) found a negative association 
between OC and markers of atherosclerosis within men but 
no significant association in women (29, 35). Prats-Puig et  al. 
(32) found a positive association with ucOC, but no significant 
association was reported for total OC (32). Reyes-Garcia et  al. 
(34) found a positive association in women only. Ma et al. (24) 
found an association between OC and plaque scores within men 
with normal glucose tolerance, but no association was reported 
with C-IMT (24). Choi et al. (41) found a positive association in 
men with total OC but no association in women or with ucOC 
(41). Yun et  al. (43) found a negative association at low levels 
of OC only (43), and Zhang et al. (42) found an association in 
unstable angina pectoris and acute myocardial infarction patients 
but not in pectoris patients with stable angina (42). The single 
longitudinal study by Kanazawa et  al. (47) showed conflicting 
results as baseline measurements demonstrated that OC was 
significantly and positively correlated with plaque score; however, 
OC was then negatively correlated with changes in plaque score 
at the end of the study (47).
Overall, in studies that conducted gender sub-analyses, more 
positive relationship outcomes between OC and measurements 
of atherosclerosis or calcification were observed within males 
than negative outcomes, while the reverse was reported within 
females. A neutral outcome was the most common finding overall 
for males and females. For the remaining studies when the study 
population was analyzed as a total, a positive outcome was the 
most common finding.
Thirty-six percent of outcomes from studies conducted in 
Asia found a negative relationship between OC and markers of 
atherosclerosis or calcification, in contrast to 6% in European 
studies and 5% in American, Canadian, Mexican, or Australian 
studies. Outcomes examined by population characteristics, 
e.g., chronic kidney disease patients, healthy adults, vascular 
problems (vascular dysfunction/coronary heart disease/athero-
sclerosis) were mixed. When examining studies that only used 
blood samples to measure OC (n = 33), i.e., excluding the OC 
positive cell studies and histological studies, no trend became 
apparent.
No trend was observed for differing methods of measuring 
calcification or atherosclerosis, and results were similar when 
examining total studies and those that used blood samples 
to assess OC. Overall, the method of calcification scoring to 
assess calcification or atherosclerosis resulted in the most non-
significant outcomes with OC measurements.
FigURe 2 | “Risk of bias” summary: green (+) indicates low-bias risk and red (–) indicates high-bias risk. The studies included in this review were all observational in 
study design and thus the risk of bias for the item “allocation concealment” was not performed and spaces were left blank.
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FigURe 4 | Funnel plot evaluating publication bias on the effect of OC 
concentration on atherosclerosis or calcification. The SE of the mean 
difference in osteocalcin concentration for each study is plotted against its 
effect size (horizontal axis). Although the distribution of the studies within the 
funnel plot does not appear symmetrical, there was no statistical evidence of 
publication bias (Egger’s statistic p = 0.279).
FigURe 3 | Meta-analysis examining osteocalcin (OC) concentration (nanograms per millilitre) differences between groups with and without vascular perturbations 
(markers of calcification or atherosclerosis).
11
Millar et al. OC and Vascular Calcification
Frontiers in Endocrinology | www.frontiersin.org July 2017 | Volume 8 | Article 183
DiScUSSiON
This review aimed to uncover whether there was a conclusive asso-
ciation between OC and vascular calcification or atherosclerosis 
in humans by performing a systematic review of the current litera-
ture. In total, 33 studies measuring blood OC concentrations and 
13 studies measuring OC positive cells or histological staining of 
OC were found through the literature searches. Overall, no clear 
association could be made between OC and extent of calcifica-
tion or atherosclerosis, which was confirmed by meta-analysis. 
However, all studies measuring OC positive cells or histological 
staining of OC showed a positive relationship with calcification 
or atherosclerosis. Some potential reasons for discrepancies in 
results were explored during the synthesis, including the method 
of OC measurement, variability in population characteristics 
and ethnicity, gender, and method of measuring calcification or 
atherosclerosis.
The majority of studies measured blood concentrations of 
total OC, ucOC, or both, while only one study measured cOC. 
No significant relationship was established for cOC, and the stud-
ies measuring total OC and/or ucOC resulted in a combination 
of positively and negatively correlated associations, as well as 
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non-significant outcomes. Within the current review, the role of 
the different forms of OC in the vasculature, i.e., ucOC or cOC, 
could not be determined as too few studies examined OC in its 
different presentations. Total OC may not be a valuable measure-
ment for risk of vascular calcification as it is suggested that ucOC 
is the biologically active form. Future research may benefit from 
focusing on the various types of OC to ascertain whether there 
is a relationship present. However, there has been difficulty in 
measuring ucOC and cOC as few assays exist and it is unclear 
which assay system provides the most accurate measurements 
due to problems with comparability and heterogeneity of OC 
(14, 66–68). OC also displays a circadian rhythmicity with a 
nocturnal peak and thus timing of blood sampling may also 
contribute to variations in results (69, 70).
Circulating mononuclear cells, EPCs, and OPCs expressing 
OC were used by studies included in this review as a form of 
OC measurement. These cells are found in the bloodstream and 
released by bone marrow. EPCs can differentiate into endothelial 
cells and play a role in angiogenesis (71). It has been hypothesized 
that OC positive EPCs are involved in the mechanism of calci-
fication by mediating abnormal vascular repair. This is thought 
to be as a result of the activation of osteogenic genes within the 
EPCs. EPCs are considered to be part of the initial response to 
vessel damage; however, instead of promoting normal repair they 
express an “osteogenic transcriptosome” which promotes calcifi-
cation. This is further supported by gene expression analyses of 
CD34+ cells showing expression of bone mineralization related 
proteins such as Runx2 and BMP-2. It has been proven that OC 
is expressed by atherosclerotic plaques and VSMCs, which have 
differentiated as part of the process of calcification already (72) 
and so studying the association between cells expressing OC and 
calcification could provide further direction for future studies. 
All the articles reviewed in this study found a significant, positive 
correlation between OC positive cells and increased calcification 
or atherosclerosis.
Histological staining for OC resulted in similarly positive find-
ings. The positive correlation found in all these studies between 
OC and calcification supports the hypothesis that OC expressed 
by these cells may contribute to the initial calcification of the ves-
sels. This is comparable to Idelevich et al. (16) whose observations 
suggest OC is an active contributor to the mineralization process 
and stimulates differentiation of chondrocytes and VSMCs (16). 
These observations indicate the potential clinical implications of 
OC in detecting subclinical atherosclerosis and spotty calcifica-
tions. Conflicting results arise only when OC is measured in blood 
samples, suggesting a need for ucOC and cOC to be measured 
separately with reliable reproducible assays to disentangle their 
functions.
All the studies examined in this systematic review, except 
two, were cross-sectional observational studies. These, although 
useful, are also limited in their interpretation as a cause–effect 
relationship cannot be concluded from the results. The mecha-
nism behind calcification remains very much unresolved and so 
the role, if any, of OC in the process is difficult to identify. The 
longitudinal study by Kanazawa et al. showed conflicting results 
between baseline measurements and final measurements. These 
results demonstrated that initially, total OC was significantly and 
positively correlated with carotid plaque score (47). However, 
OC was negatively correlated with changes in plaque score even 
after adjustment with atherosclerosis-related risk factors at the 
end of the study. This suggested that OC was relevant to calcifica-
tion at both extremes, forming a U-shaped association. It was 
therefore hypothesized that atherosclerotic plaques may initially 
promote OC secretion but eventually the increased level of OC 
may suppress the progression of atherosclerosis or calcification. 
Furthermore, the longitudinal study by Yang et al. (62) reported 
that very high numbers of early circulating OC positive EPCs 
tended to be associated with to the risk of all-cause mortality 
(62). Further studies in a similar prospective longitudinal style 
should be carried out to confirm the hypotheses suggested. 
This may provide a reason for the numerous conflicting cross-
sectional studies that have studied populations at different 
phases of disease.
No clear trends could be seen as a result of gender, although 
it can be noted more negative than positive outcomes between 
OC and calcification or atherosclerosis were observed in 
men, while the opposite was observed for women. Gender 
differences in OC actions have been reported elsewhere, for 
example in diabetes and fertility (5, 73). Due to the variety 
of population characteristics included the studies reviewed, 
associations could not be concluded between particular popu-
lations and study results. Most participants were over 50 years 
of age (data not shown), and this may seem reasonable as the 
risk of vascular calcification and atherosclerosis increases with 
age; however, with an increase in age also comes an increase 
in comorbidities, which could have influenced the results 
found in some studies. In addition, OC concentrations are 
influenced by medication including glucocorticoid therapy, 
antiresorptive agents and vitamin D treatment (74). Not all 
the studies accounted for these being potential confounding 
factors.
An interesting study by Namba et al. (75) examined the effect 
on bone metabolism markers and atherosclerosis measures in 
patients with atrial fibrillation when switching from warfarin 
(a vitamin K antagonist) to rivaroxaban (75). This study found 
ucOC concentrations to decrease after 6 months of rivaroxaban 
treatment as vitamin K was no longer prohibited. Concomitantly, 
osteopontin (an atherosclerosis-related marker) was decreased, 
bone alkaline phosphatase (a bone formation marker) was 
increased and PWV and augmentation index were significantly 
decreased. The availability of vitamin K allows for γ-carboxylation 
of ucOC to cOCN, and the reported improvements in atheroscle-
rosis markers suggest and allude to the importance and potential 
clinical relevance of the differing presentations of OC, and their 
usefulness to detect at risk populations.
Ethnicity may play a role in the conflicting results of the studies 
in this review. Thirty-seven percent of studies conducted in Asia 
reported negative relationships between OC and calcification or 
atherosclerosis, compared to 6% of European studies. Studies in 
both populations used a combination of endpoints measuring 
calcification or atherosclerosis, showing that this variation did 
not affect this comparison. Within 10 studies that had a sample 
size >300, 1 reported a positive outcome, 7 reported negative out-
comes, with the remaining two finding no significant outcomes. 
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Eight of these larger studies were conducted in Asia, thus the 
negative outcomes may be reflective of higher statistical power or 
ethnicity or a combination of both.
The meta-analysis performed providing adequate data on OC 
concentration confirmed findings from the qualitative compo-
nent of this systematic review. The large heterogeneity reported 
again questions the reliability of serum or plasma measurements 
of OC concentration, the accuracy of methods of measurement 
of total OC and its undercarboxylated and carboxylated forms, 
and the need for well-defined studies with a primary aim of 
assessing OC’s role in vascular calcification and atherosclerosis. 
The heterogeneity present in the meta-analysis can be further 
explained by the variety of study populations (kidney disease, 
diabetes or glucose intolerance, postmenopausal women, and 
hypertension) and the different methods employed to distin-
guish between those with and without vascular calcification or 
atherosclerosis and varying severities therein.
There are a few limitations in this review, which should be 
considered. Despite a thorough search of the two databases 
chosen, the addition of more databases may have widened the 
search to increase the number of results and hence improve 
the reliability and validity of the findings. However, the review 
was carried out by two independent reviewers, and searches 
generated were analyzed separately and then compared. Only 
one study analyzed cOC, which limits the results reported here. 
Furthermore, due to the observational nature of the studies 
included, only associations can be drawn and no causal relation-
ships can be concluded.
In conclusion, no clear association can be made between OC 
and vascular calcification or atherosclerosis from the currently 
available published research. This review has highlighted themes, 
which may influence OC within differing populations leading to 
inconclusive results. In addition, the various forms of circulating 
OC should be separately measured and considered in future stud-
ies. Longitudinal studies may provide more insightful results as to 
the potential pathological effects of OC.
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